Dianthus Therapeutics (DNTH) Net Margin: 2022-2025
Historic Net Margin for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to -9,250.00%.
- Dianthus Therapeutics' Net Margin fell 807804.00% to -9,250.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -4,076.22%, marking a year-over-year decrease of 281877.00%. This contributed to the annual value of -1,355.24% for FY2024, which is 18086.00% up from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' Net Margin is -9,250.00%, which was up 43.37% from -16,333.68% recorded in Q2 2025.
- Dianthus Therapeutics' 5-year Net Margin high stood at -668.20% for Q3 2022, and its period low was -16,333.68% during Q2 2025.
- Its 3-year average for Net Margin is -3,679.31%, with a median of -1,594.37% in 2023.
- Per our database at Business Quant, Dianthus Therapeutics' Net Margin skyrocketed by 42,241bps in 2024 and then tumbled by 1,539,455bps in 2025.
- Quarterly analysis of 4 years shows Dianthus Therapeutics' Net Margin stood at -855.57% in 2022, then crashed by 161,203bps to -2,467.61% in 2023, then soared by 36,157bps to -2,106.03% in 2024, then tumbled by 807,804bps to -9,250.00% in 2025.
- Its last three reported values are -9,250.00% in Q3 2025, -16,333.68% for Q2 2025, and -2,526.74% during Q1 2025.